Atlas Trials

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Clinical trial NCT05103891 · UNKNOWN

Trial details

NCT number
NCT05103891
Sponsor
Pierre Fabre Medicament
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
MelanomaBRAF V600 MutationUnresectable MelanomaMetastatic Melanoma
Start date
2021-09-03
Primary completion
2021-11-29
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.